NDAORALCAPSULEPriority Review
Approved
Dec 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
METOPIRONE (metyrapone) by Esteve is adrenal steroid synthesis inhibitors [moa]. Approved for adrenal steroid synthesis inhibitor [epc]. First approved in 1961.
Drug data last refreshed 7m ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Metyrapone is an oral adrenal steroid synthesis inhibitor approved in 1961 that blocks 11β-hydroxylase, reducing cortisol production. It is used to manage severe hypercortisolism and Cushing's syndrome by decreasing adrenal steroid synthesis. The drug acts as a diagnostic and therapeutic agent for conditions requiring urgent cortisol suppression.
$0.001BPart D
LOE ApproachingUltra-niche specialty market with minimal team expansion; roles are highly specialized and limited to rare disease expertise.
Mechanism of Action
Adrenal Steroid Synthesis Inhibitors
Pharmacologic Class:
Adrenal Steroid Synthesis Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Metyrapone as Additive Treatment in Major Depression
Started May 1998
63 enrolled
Major Depressive Disorder
Career Relevance
Metyrapone is a highly specialized, low-volume product with minimal current job openings; working on this product develops deep endocrinology and rare disease expertise valuable for niche pharma careers. This role suits candidates seeking intimate knowledge of a complex therapeutic area rather than large-scale commercial growth.
Specialty/Rare Disease Physician Liaison
Worked on METOPIRONE at Esteve? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.